| Ticker Details |
Emergent Biosolutions, Inc.
Emergent BioSolutions Inc is a biotechnology company operating in two divisions: biodefense and biosciences. The company focuses on countermeasures that address public health threats around hematology and oncology therapeutics.
|
| IPO Date: |
December 1, 2006 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$260.47M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.63 | 2.56%
|
| Avg Daily Range (30 D): |
$0.18 | 2.91%
|
| Avg Daily Range (90 D): |
$0.21 | 2.75%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.56M |
| Avg Daily Volume (30 D): |
.96M |
| Avg Daily Volume (90 D): |
.74M |
| Trade Size |
| Avg Trade Size (Sh.): |
107 |
| Avg Trade Size (Sh.) (30 D): |
79 |
| Avg Trade Size (Sh.) (90 D): |
72 |
| Institutional Trades |
| Total Institutional Trades: |
5,157 |
| Avg Institutional Trade: |
$2.46M |
| Avg Institutional Trade (30 D): |
$.95M |
| Avg Institutional Trade (90 D): |
$1.1M |
| Avg Institutional Trade Volume: |
.08M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.06M |
| Avg Closing Trade (30 D): |
$.94M |
| Avg Closing Trade (90 D): |
$1.08M |
| Avg Closing Volume: |
110.31K |
|
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
$-3.41
|
$-3.49
|
$.13
|
|
Diluted EPS
|
$-3.47
|
$-3.49
|
$.07
|
|
Revenue
|
$770.2M
|
$234.3M
|
$156.1M
|
|
Gross Profit
|
$430.3M
|
$137.2M
|
$84.1M
|
|
Net Income / Loss
|
$-176.8M
|
$-180.2M
|
$6.8M
|
|
Operating Income / Loss
|
$-66M
|
$-125.1M
|
$10.5M
|
|
Cost of Revenue
|
$339.9M
|
$97.1M
|
$72M
|
|
Net Cash Flow
|
$-130.1M
|
$-20.6M
|
$-47.6M
|
|
PE Ratio
|
|
|
|
|
|
|
